Angela Hamel
Psychiatric/Mental Health · Spokane, WANPI 1548760747
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 52.1% of the total. 2024 is the largest year on record at $2,535, 3.0 times the $856 reported in 2021. Among psychiatric/mental health clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Supernus Pharmaceuticals, Inc.$442
- Sunovion Pharmaceuticals Inc.$359
- Teva Pharmaceuticals USA, Inc.$347
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$211
- Johnson & Johnson$127
- plus $527 from 11 others
What the payments were for
- Consulting fees$1153%
- Speaking & faculty fees$2,04649%
- Food & beverage$1,99547%
- Education$471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $2,190 |
| Supernus Pharmaceuticals, Inc. | 31 | $442 |
| Sunovion Pharmaceuticals Inc. | 26 | $359 |
| Teva Pharmaceuticals USA, Inc. | 33 | $347 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $211 |
| Johnson & Johnson | 7 | $127 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $90 |
| Neurocrine Biosciences, Inc. | 5 | $89 |
| AbbVie | 4 | $61 |
| Alkermes, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Eisai Inc. | 2 | $34 |
| Corium, LLC | 2 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,203 in reported general payments places this provider in the 90th percentile of 931 psychiatric/mental health providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 126 | $192,766 |
| AustedoDeutetrabenazine | 18 | $119,425 |
| Austedo XrDeutetrabenazine | 11 | $97,076 |
| RexultiBrexpiprazole | 30 | $43,911 |
| Invega SustennaPaliperidone Palmitate | 12 | $41,962 |
| MounjaroTirzepatide | 26 | $28,368 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $21,072 |
| Aripiprazole | 71 | $9,120 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 22 | $8,866 |
| TrintellixVortioxetine Hydrobromide | 16 | $7,609 |
| BelsomraSuvorexant | 13 | $6,939 |
| Eszopiclone | 27 | $3,875 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 51 | $2,835 |
| Methylphenidate ErMethylphenidate Hcl | 26 | $2,828 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 59 | $2,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna | $127 | $234,728138 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $347 | $216,50129 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,190 | $43,91130 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $16 | $28,70343 claims |
| Axsome Therapeutics, Inc.Auvelity | $36 | $21,07218 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $90 | $7,60916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 931 psychiatric/mental health providers in Washington.
Other psychiatric/mental health in Spokane
- Dawn MasonSpokane$25K
- Favor OsakweSpokane$10K
- Colleen MooreSpokane$8K
- Nicholas GoodwinSpokane$5K
- Margaret KyakuwaSpokane$5K
- Kiira TietjenSpokane$5K
- Angela CombsRichland$121K
- Ashley McGinnisAuburn$26K
- Courtney YantPuyallup$26K
- Jennifer WilsonYakima$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.